Various Factors Influence Cardiac Troponin Concentrations
By LabMedica International staff writers Posted on 14 Sep 2017 |

Image: The ARCHITECT i2000SR immunoassay analyzer (Photo courtesy of Abbott Laboratories).
Cardiovascular diseases are the second most common cause of death in Japan, and the number of new cases is continuously growing. Among the cardiovascular diseases, one-third is attributed to ischemic heart diseases including acute myocardial infarction (AMI).
Cardiac troponin I is a protein that is specifically expressed in cardiomyocytes and is eluted in the blood when cardiomyocytes are injured such as by ischemia. Due to its specificity, cardiac troponin I has become one of the most reliable biomarkers for the diagnosis of AMI.
Scientists at the Japanese Red Cross Medical Center (Tokyo, Japan) and their colleagues enrolled a total of 698 apparently healthy individuals (385 females and 313 males) between the ages of 23 and 86 who visited the Medical Center for a health checkup from January through April in 2014 were included in this study.
The team performed routine biochemistry tests on a BioMajesty JCA-BM6070 clinical biochemistry analyzer that included the assays for aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma glutamyl transferase (GGT), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), creatinine (Cre), hemoglobin A1c (HbA1c), and lactate dehydrogenase (LDH). Serum samples were used for the measurement of all the assays except for HbA1c, which was measured with whole-blood samples.
The Abbott Laboratories’ STAT high-sensitive troponin I (hsTnI) was performed for the measurement of cardiac troponin I on Architect i2000. The limit of detection (LoD) of the assay was 1.9 pg/mL, the lowest concentration where 10% coefficient of variation (CV) was supported was 4.7 pg/mL and the overall 99th percentile was 26.2 pg/mL. The CardioPhase high-sensitive C-reactive protein (hsCRP) tests were performed for the measurement of CRP. The limit of detection (LoD) of the assay was 0.175 mg/L, the CV was 7.6% at 0.410 mg/L and the reference value was 3 mg/L.
The scientists found that the 99th percentile of the hsTnI in the overall population was 22.5 pg/mL, 17.7 pg/mL for females and 30.6 pg/mL for males. The median of the hsTnI in the overall population was 3.2 pg/mL, 2.6 pg/mL for females and 4.0 pg/mL for males. The age and gender had a significant influence on these values. The troponin I level also showed significant associations with the body mass index (BMI), the gamma glutamyl transferase (GGT), lactate dehydrogenase (LDH), estimated glomerular filtration rate (eGFR), and cardiac abnormalities by electrocardiography (ECG), but not with the high-sensitive C-reactive protein (hsCRP) level.
The authors concluded that the 99th percentiles of the troponin I measured in the general population in Japan were comparable as the ones derived in the USA, Germany, and Singapore. The troponin I level was dependent on the gender, age, BMI, and cardiac abnormalities found by electrocardiogram (ECG) but not by the hsCRP level. The study was published on August 1, 2017, in the Journal of Clinical Laboratory Analysis.
Related Links:
Japanese Red Cross Medical Center
Cardiac troponin I is a protein that is specifically expressed in cardiomyocytes and is eluted in the blood when cardiomyocytes are injured such as by ischemia. Due to its specificity, cardiac troponin I has become one of the most reliable biomarkers for the diagnosis of AMI.
Scientists at the Japanese Red Cross Medical Center (Tokyo, Japan) and their colleagues enrolled a total of 698 apparently healthy individuals (385 females and 313 males) between the ages of 23 and 86 who visited the Medical Center for a health checkup from January through April in 2014 were included in this study.
The team performed routine biochemistry tests on a BioMajesty JCA-BM6070 clinical biochemistry analyzer that included the assays for aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma glutamyl transferase (GGT), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), creatinine (Cre), hemoglobin A1c (HbA1c), and lactate dehydrogenase (LDH). Serum samples were used for the measurement of all the assays except for HbA1c, which was measured with whole-blood samples.
The Abbott Laboratories’ STAT high-sensitive troponin I (hsTnI) was performed for the measurement of cardiac troponin I on Architect i2000. The limit of detection (LoD) of the assay was 1.9 pg/mL, the lowest concentration where 10% coefficient of variation (CV) was supported was 4.7 pg/mL and the overall 99th percentile was 26.2 pg/mL. The CardioPhase high-sensitive C-reactive protein (hsCRP) tests were performed for the measurement of CRP. The limit of detection (LoD) of the assay was 0.175 mg/L, the CV was 7.6% at 0.410 mg/L and the reference value was 3 mg/L.
The scientists found that the 99th percentile of the hsTnI in the overall population was 22.5 pg/mL, 17.7 pg/mL for females and 30.6 pg/mL for males. The median of the hsTnI in the overall population was 3.2 pg/mL, 2.6 pg/mL for females and 4.0 pg/mL for males. The age and gender had a significant influence on these values. The troponin I level also showed significant associations with the body mass index (BMI), the gamma glutamyl transferase (GGT), lactate dehydrogenase (LDH), estimated glomerular filtration rate (eGFR), and cardiac abnormalities by electrocardiography (ECG), but not with the high-sensitive C-reactive protein (hsCRP) level.
The authors concluded that the 99th percentiles of the troponin I measured in the general population in Japan were comparable as the ones derived in the USA, Germany, and Singapore. The troponin I level was dependent on the gender, age, BMI, and cardiac abnormalities found by electrocardiogram (ECG) but not by the hsCRP level. The study was published on August 1, 2017, in the Journal of Clinical Laboratory Analysis.
Related Links:
Japanese Red Cross Medical Center
Latest Clinical Chem. News
- Low-Cost Portable Screening Test to Transform Kidney Disease Detection
- New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
- Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
- Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
- AI-Powered Raman Spectroscopy Method Enables Rapid Drug Detection in Blood
- Novel LC-MS/MS Assay Detects Low Creatinine in Sweat and Saliva
- Biosensing Technology Breakthrough Paves Way for New Methods of Early Disease Detection
- New Saliva Test Rapidly Identifies Paracetamol Overdose
- POC Saliva Testing Device Predicts Heart Failure in 15 Minutes
- Screening Tool Detects Multiple Health Conditions from Single Blood Drop
- Integrated Chemistry and Immunoassay Analyzer with Extensive Assay Menu Offers Flexibility, Scalability and Data Commutability
- Rapid Drug Test to Improve Treatment for Patients Presenting to Hospital
- AI Model Detects Cancer at Lightning Speed through Sugar Analyses
- First-Ever Blood-Powered Chip Offers Real-Time Health Monitoring
- New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections
- 3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
Channels
Molecular Diagnostics
view channel
Novel Autoantibody Against DAGLA Discovered in Cerebellitis
Autoimmune cerebellar ataxias are strongly disabling disorders characterized by an impaired ability to coordinate muscle movement. Cerebellar autoantibodies serve as useful biomarkers to support rapid... Read more
Gene-Based Blood Test Accurately Predicts Tumor Recurrence of Advanced Skin Cancer
Melanoma, an aggressive form of skin cancer, becomes extremely difficult to treat once it spreads to other parts of the body. For patients with metastatic melanoma tumors that cannot be surgically removed... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read morePathology
view channel
Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures
Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more
New Error-Corrected Method to Help Detect Cancer from Blood Samples Alone
"Liquid biopsy" technology, which relies on blood tests for early cancer detection and monitoring cancer burden in patients, has the potential to transform cancer care. However, detecting the mutational... Read more
"Metal Detector" Algorithm Hunts Down Vulnerable Tumors
Scientists have developed an algorithm capable of functioning as a "metal detector" to identify vulnerable tumors, marking a significant advancement in personalized cancer treatment. This breakthrough... Read more
Novel Technique Uses ‘Sugar’ Signatures to Identify and Classify Pancreatic Cancer Cell Subtypes
Pancreatic cancer is often asymptomatic in its early stages, making it difficult to detect until it has progressed. Consequently, only 15% of pancreatic cancers are diagnosed early enough to allow for... Read moreTechnology
view channel
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more